ReviewStem cell research & therapy2026
Secretome as a novel regenerative strategy for atopic dermatitis: a comprehensive review.
Review in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tuning Secretomes for Regenerative Medicine.Biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by disrupted epidermal barrier function, immune dysregulation, and persistent inflammation. Affecting both children and adults, AD significantly impairs quality of life due to its visible symptoms and associated psychosocial and economic burdens. Traditional treatments such as application of topical corticosteroids, calcineurin inhibitors, moisturizers and antibiotics, while managing symptoms, often fall short of providing long-term solutions and can lead to adverse effects over time. This review explores innovative approaches to AD management, focusing on the therapeutic potential of the secretome. The secretome, a collection of bioactive molecules secreted by cells, has shown promise in promoting tissue regeneration and modulating immune responses. This study investigates how secretome therapy can restore the integrity of keratinocytes, the primary cells responsible for maintaining the skin barrier, which is severely compromised in AD. Using in vitro AD models, the secretome's potential to reduce inflammation and enhance skin barrier function is evaluated. By targeting the underlying mechanisms of AD, secretome-based therapies could offer a novel approach to treatment, providing both regenerative and anti-inflammatory benefits. The findings from this study may pave the way for more effective, non-invasive treatments that address the root causes of AD, potentially reducing the disease's impact and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.